These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

497 related items for PubMed ID: 17926832

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab.
    Sandborn WJ, Rutgeerts P, Feagan BG, Reinisch W, Olson A, Johanns J, Lu J, Horgan K, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF.
    Gastroenterology; 2009 Oct; 137(4):1250-60; quiz 1520. PubMed ID: 19596014
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Is keeping the colon the ultimate marker of success in ulcerative colitis?
    Nguyen GC, Prather CM.
    Gastroenterology; 2009 Oct; 137(4):1204-6. PubMed ID: 19717125
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease.
    Clare DF, Alexander FC, Mike S, Dan G, Allan F, Lisa W, Peter HJ.
    Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):71-5. PubMed ID: 19060632
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Infliximab for the treatment of ulcerative colitis.
    Eshuis EJ, Bemelman WA, Stokkers PC.
    Expert Rev Gastroenterol Hepatol; 2009 Jun; 3(3):219-29. PubMed ID: 19485804
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Inflammatory diseases of the intestines].
    Felley C, Guyot J, Hess J, Mottet C, Delarive J, Michetti P.
    Rev Med Suisse; 2006 Jan 18; 2(49):191-4, 196-8, 201-3. PubMed ID: 16493962
    [Abstract] [Full Text] [Related]

  • 17. Timing infliximab therapy in pediatric Crohn's disease.
    Kirschner BS, Huo D.
    Gastroenterology; 2007 Mar 18; 132(3):1167-70. PubMed ID: 17383435
    [No Abstract] [Full Text] [Related]

  • 18. [Biological therapy as treatment of inflammatory bowel diseases].
    Agnholt J.
    Ugeskr Laeger; 2008 Jun 09; 170(24):2152-6. PubMed ID: 18565302
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
    Jahnsen J, Detlie TE, Vatn S, Ricanek P.
    Expert Rev Gastroenterol Hepatol; 2015 Jun 09; 9 Suppl 1():45-52. PubMed ID: 26395534
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.